Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
US Army
Fish and Richardson
Argus Health
Deloitte
AstraZeneca
Cantor Fitzgerald
Harvard Business School
Chubb

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,298,580

« Back to Dashboard

Which drugs does patent 8,298,580 protect, and when does it expire?

Patent 8,298,580 protects TROKENDI XR and is included in one NDA.

This patent has eleven patent family members in eight countries.
Summary for Patent: 8,298,580
Title:Sustained-release formulations of topiramate
Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
Inventor(s): Liang; Likan (Boyds, MD), Wang; Hua (Clarksville, MD), Bhatt; Padmanabh P. (Rockville, MD), Vieira; Michael L. (Gaithersburg, MD)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:12/926,931
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,298,580
Patent Claim Types:
see list of patent claims
Formulation; Compound; Composition; Dosage form; Use;

Drugs Protected by US Patent 8,298,580

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-001 Aug 16, 2013 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF EPILEPSY ➤ Try a Free Trial
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-001 Aug 16, 2013 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE ➤ Try a Free Trial
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF EPILEPSY ➤ Try a Free Trial
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,298,580

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,555,004 Sustained-release formulations of topiramate ➤ Try a Free Trial
8,877,248 Sustained-release formulations of topiramate ➤ Try a Free Trial
8,298,576 Sustained-release formulations of topiramate ➤ Try a Free Trial
9,549,940 Sustained-release formulations of topiramate ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,298,580

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007319141 ➤ Try a Free Trial
Canada 2618240 ➤ Try a Free Trial
Germany 07870164 ➤ Try a Free Trial
European Patent Office 1973528 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
US Army
Colorcon
Daiichi Sankyo
AstraZeneca
Teva
Argus Health
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.